Workflow
兽用灭活疫苗
icon
Search documents
“滨企创世界”行动工作动态(2026年第3期)
Xin Lang Cai Jing· 2026-01-18 10:10
Group 1 - The "Binzhou Enterprises Create the World" initiative has been actively supported by various levels of government, creating a strong atmosphere for enterprises to expand internationally [1][2] - The initiative includes a special publication to showcase successful practices and experiences from different departments [1] - The city is focusing on enhancing the business environment, with a commitment to making it easier for enterprises and entrepreneurs to thrive [2] Group 2 - A meeting was held with the COO of Thailand's Wanpu Group, where the company expressed intentions to increase investments in clean renewable energy in Binzhou [1] - The "14th Five-Year Plan" entrepreneur consultation meeting was conducted to gather feedback from local business leaders [1] Group 3 - The Municipal Bureau of Commerce organized specialized training for pharmaceutical and chemical enterprises to enhance their export capabilities [5][9] - A cross-border e-commerce business survey was conducted to understand the needs and suggestions of key enterprises in the sector [7] Group 4 - The Municipal Foreign Affairs Office hosted a cooperation meeting with the Netherlands' De Rijke Group to discuss logistics and international business collaboration [6] - A biotechnology industry matchmaking event was organized with South African companies to explore cooperation in veterinary vaccines [11] Group 5 - The Municipal Trade Promotion Council has been facilitating the certification process for enterprises, issuing a total of 336 certificates of origin to support international trade [12] - The People's Bank of China in Binzhou is working on implementing a unified fund pool policy to provide better financial services for foreign trade and investment [13]
普莱柯: 普莱柯关于部分募集资金专户销户完成的公告
Zheng Quan Zhi Xing· 2025-05-22 12:26
Fundraising Overview - The company has been approved by the China Securities Regulatory Commission to issue no more than 64,299,200 new shares, of which 31,420,573 shares were actually issued at a price confirmed on September 5, 2022 [1] - The funds raised are managed in accordance with regulatory guidelines and the company's internal management system, with specific accounts opened at various banks for the purpose of fund storage and management [1][2] Fund Usage and Account Status - The company has established special accounts for the raised funds at several banks, including China Construction Bank and Minsheng Bank, for projects such as the production of inactivated vaccines and the expansion of biological product workshops [2] - As of the announcement date, the status of the fundraising accounts is active, with specific projects linked to each account [2] Project Completion and Fund Reallocation - The company has concluded certain fundraising projects, specifically the "inactivated vaccine production project" and the "product quality inspection workshop project," and has decided to permanently allocate the remaining funds to working capital [3] - Following the completion of these projects, the corresponding fundraising accounts will be closed, and the related storage agreements will be terminated [3]